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 Abstract 
Tripartite motif family-like 2 (TRIML2), a member of the TRIM proteins family, is 
closely related to Alzheimer’s disease, however, no studies of TRIML2 have been 
published in the cancer research literature. In the current study, we investigated the 
expression level of TRIML2 and its molecular mechanisms in human oral squamous 
cell carcinoma (OSCC); reverse transcriptase-quantitative polymerase chain 
reaction, immunoblot analysis, and immunohistochemistry showed that TRIML2 is 
up-regulated significantly in OSCCs in vitro and in vivo. TRIML2 knockdown OSCC 
cells showed decreased cellular proliferation by cell-cycle arrest at G1 phase that 
resulted from down-regulation of CDK4, CDK6, and cyclin D1 and up-regulation of 
p21Cip1 and p27Kip1. Surprisingly, resveratrol, a polyphenol, led to not only      
down-regulation of TRIML2 but also cell-cycle arrest at G1 phase similar to   
TRIML2 knockdown experiments. Taken together, we concluded that TRIML2 might 
play a significant role in tumoral growth and that resveratrol may be a new drug for 
treating OSCC by interfering with TRIML2 function. 
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 1. Introduction 
The family of tripartite motif (TRIM) proteins in humans has 77 members [1], 
almost all of which have an N-terminal RING ﬁnger, B-boxes, and a coiled-coil 
domains. The TRIM family members are divided into 12 subfamilies (C-I to C-Ⅺ and 
an unclassified group) that were classified based on the differences in their C-terminal 
domains [2,3]. TRIM proteins play significant roles in a range of processes including 
tumoral suppression, DNA damage, stem cell differentiation, and immune reactivity 
against viral infections, particularly human immunodeficiency virus [4–8].  
TRIM family-like 2 (TRIML2) belongs to an unclassified group because it lacks a 
RING-ﬁnger domain [1,3]. Polymorphisms in TRIML2 and their haplotypes are related 
significantly to Alzheimer’s disease, suggesting that TRIML2 is a biomarker for the 
diagnosis of Alzheimer’s disease [9]. Despite increasing recognition of the significant 
cellular functions of TRIML2, the biochemical basis for these mechanisms is not well 
understood, and no reports in the cancer research literature have addressed this.  
In the current study, overexpressed TRIML2 was seen in human oral squamous 
cell carcinoma (OSCC) cells and primary OSCCs. We also reported that TRIML2 was 
correlated with cell-cycle arrest at G1 phase using TRIML2 knockdown models and its 
novel specific inhibitor, resveratrol.   
 2. Materials and methods 
2.1. Ethics statement 
The ethics committee of Chiba University approved the study protocol (protocol 
number 680). All patients provided written informed consent, which was obtained 
before the experiments were conducted. 
 
2.2. Cells and clinical OSCC tissue samples 
Ten OSCC cells were used for in vitro experiments. [10–19]. We extracted human 
normal oral keratinocytes (HNOKs) from healthy young patients as control cells and 
cultured them as described previously [10,11]. OSCCs and normal oral tissue samples 
(n=100) were collected from patients with OSCC at Chiba University Hospital. 
 
2.3. Gene expression analysis 
We isolated total RNA from OSCC cells incubated subconfluently for generating 
cDNA and performed reverse transcription-quantitative polymerase chain reaction  
(RT-qPCR) as described previously [10,11,20]. The following primer sequences were 
used for RT-qPCR; TRIML2, 5′-CACATGGTGTGTGGGATACAA-3′ and 5′-
CCTCGATGTGTTCAATATTTCCT-3′; and glyceraldehyde 3-phosphate 
 dehydrogenase (GAPDH), 5′-AGCCACATCGCTCAGACAC-3′ and 5′-
GCCCAATACGACCAAATCC-3′. 
 
2.4. Immunoblot analysis 
We performed immunoblot analysis as described previously [17,21]. The 
antibodies were rabbit anti-TRIML2 polyclonal antibody (Abcam, Cambridge, UK), 
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p21Cip1, p27Kip1, cyclin 
D1, CDK2, and CDK4 (Cell Signaling Technology Japan, Tokyo, Japan).  
 
2.5. Immunohistochemistry (IHC) 
We performed IHC and calculated the IHC score described previously [17,21–
25]. We evaluated the TRIML2 scores from 100 patients with OSCC and classified 
TRIML2 as positive and negative using the median score of all OSCCs as the cut-off 
points [26]. In this case, the IHC score over 117 was taken as TRIML2 positive.  
 
2.6. Transfection with shRNA 
 We established TRIML2 knockdown cells derived from the Sa3 and SAS cells 
using TRIML2 shRNA (shTRIML2) and control shRNA (shMock) vectors, respectively 
(Santa Cruz Biotechnology). The protocol was described previously [14]. 
 
2.7. Cellular growth 
We analyzed the cellular growth in shTRIML2 and shMock cells to assess the 
effect of TRIML2 knockdown on cellular proliferation. The protocol was described 
previously [17,27,28]. 
 
2.8. Cell-cycle analysis 
We conducted cell-cycle analysis by flow cytometry using the BD AccuriTM C6 
Flow Cytometer (Becton-Dickinson, San Diego, CA, USA). The protocol was described 
previously [14,23,29].  
 
2.9. Resveratrol treatment 
To investigate a correlation between TRIML2 and resveratrol (Sigma-Aldrich, St. 
Louis, MO, USA), we treated Sa3 and SAS cells with resveratrol for 48 h. After 
treatment, we extracted total RNA, generated complementary DNA, and performed RT-
 qPCR. We also extracted protein for immunoblot analysis and evaluated whether 
resveratrol affected the cellular proliferation and cell-cycle by treating the Sa3 and SAS 
cells with resveratrol for 48 h. In the cellular proliferation assay, the cells were cultured 
with resveratrol, and dimethylsulfoxide served as the experimental control. 
 
2.10. Statistical analysis 
Student’s t-test, Fisher’s exact test, and Mann-Whitney U-test were performed to 
identify significance correlations. All data are expressed as the mean ± the standard 
error of the mean. 
  
 3. Results 
3.1. Evaluation of TRIML2 expression OSCC cells and primary OSCCs 
RT-qPCR and immunoblot data showed that TRIML2 expression was up-
regulated significantly (p < 0.05) in all OSCC cells compared with the HNOKs (Fig. 
1A, B). Fig. 1C shows representative IHC results of TRIML2 in normal and primary 
OSCC tissues. The IHC scores ranged from 34 to 132 (median, 64) in normal oral 
tissues and 69 to 187 (median, 117) in OSCC tissues (Fig. 1D) (p < 0.05). Table 1 shows 
the correlation between the TRIML2 expression status and clinical classification of the 
patients with OSCC. Among the clinical classifications, the TRIML2 expression level 
was correlated significantly (p < 0.05) with the primary tumoral size (Table 1).  
 
3.2. Establishment of TRIML2 knockdown cells 
We chose Sa3 and SAS cells for knockdown experiments because higher 
TRIML2 expression levels were observed in those OSCC cell lines. RT-qPCR and 
immunoblot analysis showed that TRIML2 was down-regulated in the shTRIML2 cells 
compared with the shMock cells (Fig. 2A, B, respectively). No morphologic changes in 
the TRIML2 knockdown cells were seen during microscopy. 
 
 3.3. Cellular proliferation assay of TRIML2 knockdown cells 
To evaluate the effect of the TRIML2 knockdown on cellular growth, we 
performed a cellular proliferation assay that showed significantly (p < 0.05) decrease 
cellular growth in the shTRIML2 cells compared with the shMock cells (Fig. 2C). 
 
3.4. Cell-cycle analysis of TRIML2 knockdown cells 
The cell-cycle analysis showed that the percentage of the shTRIML2 cells at G1 
phase increased significantly (p < 0.05) compared with the shMock cells (Fig. 2D). 
Evaluation of the protein expression levels of G1 phase-related proteins in the 
shTRIML2 cells showed that CDK2, CDK4, and cyclin D1 were down-regulated, and 
p21Cip1 and p27Kip1 were up-regulated in the shTRIML2 cells (Fig. 2E). These results 
indicated that the shTRIML2 cells suppressed cellular proliferation by cell-cycle arrest 
at G1 phase. 
 
3.5. Effect of treatment with resveratrol 
After resveratrol treatment (50 µM, 48 h), the TRIML2 expression levels 
decreased in both Sa3 and SAS cell lines compared with the control (Fig. 3A, B). To 
assess the effect of resveratrol on cellular growth, we performed cellular proliferation 
 assay that showed that the cellular growth of the resveratrol-treated cells was 
significantly (p < 0.05) lower than that of the control cells (Fig. 4A). The cell-cycle 
analysis, showed that the percentage of the resveratrol-treated cells in G1 phase was 
significantly (p < 0.05) higher than that of the control cells (Fig. 4B). Evaluation of the 
protein levels of CDK2, CDK4, cyclin D1, p21Cip1, and p27Kip1, showed that the cyclin 
D1, CDK2, and CDK4 protein levels were down-regulated and the p21Cip1 and p27Kip1 
protein levels were up-regulated in the resveratrol-treated cells (Fig. 4C). The data 
indicated that resveratrol decreased cellular proliferation by cell-cycle arrest at G1 
phase similar to the effect on the TRIML2 knockdown cells. 
  
4. Discussion
The current study showed that TRIML2 expression was up-regulated in OSCCs 
and was correlated significantly with tumoral growth. The TRIML2 knockdown cells 
showed inhibited cellular growth by cell-cycle arrest at G1 phase. Furthermore, 
resveratrol, a polyphenol, led to not only down-regulation of TRIML2 but also cell-
cycle arrest at G1 phase similar to that in the TRIML2 knockdown experiments. 
Some TRIM proteins are associated with gastric, breast, prostate cancers [30–32]. 
However, the biologic functions of most TRIM proteins, including TRIML2, have not 
been well elucidated thus far. Although TRIML2 has been reported to be related to 
Alzheimer's disease, other functions and mechanisms in cancers are as yet unidentified. 
Since the current data are the first in the cancer research literature, the expression status 
of TRIML2 in other cancers need to be studied. 
P21Cip1, a strong CDK inhibitor, physically interacts with cyclins, CDK2, and 
CDK4 to control cell-cycle at G1/S phase [33,34]. The current study found that 
knockdown of TRIML2 resulted in overexpression of p21Cip1 and cell-cycle arrest at G1 
phase, suggesting that p21Cip1 is regulated by the TRIML2 expression status. 
Resveratrol, an important natural compound in grapes and peanuts, have various 
inhibitory effects against aging and diabetes [35–44]. Resveratrol also is associated with 
 several cancer-related genes; however, no published studies have reported a direct 
correlation between resveratrol and TRIML2. Furthermore, resveratrol leads to up-
regulation of p21Cip1 [45,46]. Interestingly, the current data strongly indicated that 
TRIML2 controls p21Cip1 expression after treatment with resveratrol. 
In summary, overexpression of TRIML2 contributed to tumoral growth at G1 
phase as seen by cell-cycle analysis, which resulted in insufficient control by down-
regulation of p21Cip1 expression (Fig. 4D). Resveratrol caused up-regulation of p21Cip1 
through the TRIML2 expression. Therefore, the expression status of TRIML2 might be 
an indicator of OSCC progression and resveratrol may be a potential new therapeutic 
drug for oral cancer therapy via TRIML2. 
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Figure legends 
Fig. 1. Evaluation of TRIML2 expression in OSCC cells and primary OSCCs. (A) RT-
qPCR analysis shows significantly (*p < 0.05, Student’s t-test) up-regulated TRIML2 
mRNA expression in all OSCC-derived cell lines compared with the HNOKs. (B) 
Immunoblot analysis shows up-regulated TRIML2 protein expression in OSCC-derived 
cell lines compared to the HNOKs. Densitometric TRIML2 protein data are normalized 
to the GAPDH protein levels. The values are expressed as a percentage of the HNOKs. 
(C) Representative IHC results of TRIML2 in normal oral tissues and primary OSCCs.
Original magnification, ×400. Scale bars, 50 µm. (D) The status of TRIML2 protein 
expression in normal counterparts and primary OSCCs (n = 100) using the IHC scoring 
system. The TRIML2 protein expression levels in OSCCs are significantly higher than 
in normal oral tissues (*p < 0.05, Student’s t-test). 
Figure 2. Establishment of the TRIML2 knockdown cells and cell-cycle analysis of 
TRIML2 knockdown cells. (A) RT-qPCR shows that the TRIML2 mRNA expression in 
shTRIML2 cells is significantly (*p < 0.05, Student’s t-test) lower than that in shMock 
cells. (B) Immunoblot analysis shows that the TRIML2 protein levels in the shTRIML2 
cells are decreased compared with the shMock cells. (C) The cellular growth of the 
shTRIML2 cells is inhibited significantly compared with the shMock cells after 4 days 
(96 h) (*p < 0.05, Student’s t-test). (D) Flow cytometric analysis shows that the 
percentage of cells at G1 phase in the shTRIML2 cells is increased markedly (*p < 0.05, 
Mann-Whitney U-test) compared with the shMock cells. (E) Immunoblot analysis 
shows down-regulation of CDK2, CDK4, and cyclin D1 and up-regulation of p21Cip1 
and p27Kip1 in the shTRIML2 cells compared with the shMock cells. 
Figure 3. Effect of treatment with resveratrol. (A) RT-qPCR shows that the TRIML2 
mRNA expression is signiﬁcantly (*p < 0.05, Student’s t-test) down-regulated after 
treatment with resveratrol in both the Sa3 and SAS cells compared with controls. (B) 
Immunoblot analysis shows down-regulated TRIML2 expression after treatment with 
resveratrol compared with controls. 
Figure 4. Effect of treatment with resveratrol. (A) The cellular growth of the 
resveratrol-treated cells is inhibited significantly compared with the control cells after 4 
days (96 h) (*p < 0.05, Student’s t-test). (B) Flow cytometric analysis shows that the 
percentage of cells at G1 phase in resveratrol-treated cells is increased markedly (*p < 
0.05, Mann-Whitney U-test) compared with controls. (C) Immunoblot analysis shows 
down-regulation of CDK2, CDK4, and cyclin D1, and up-regulation of p21Cip1 and 
p27Kip1 in resveratrol-treated cells compared with controls. (D) Schematic representation 
of inhibition of the p21Cip1 pathway by TRIML2. After treatment with resveratrol, the 
p21Cip1 expression increased with down-regulation of TRIML2, leading to cell-cycle 
arrest at G1 phase. 
 Table 1 
Correlation between TRIML2 expression and clinical classification in OSCCs.  
Clinical classification 
 
Results of immunostaining 
No. patients 
 
  
 Total 
TRIML2 
negative 
TRIML2 
positive 
p value 
Age at surgery (years)     
   < 60 26 12 14 
0.484*  
   ≧60 74 27 47 
Gender    
  Male 56 26     30 
0.686* 
  Female 44 18     26 
T-primary tumoral size    
  T1+T2 50     29     21 
0.027*† 
  T3+T4 50     17     33 
N-regional lymph node metastasis    
  Negative 66     30     36 
0.832* 
  Positive 34     14     20 
TNM Stage    
  I+ II 32     18     14 
0.054* 
  III+ IV 68     24     44 
Vascular invasion    
  Negative 82     39     43 
0.307* 
  Positive 18      6     12 
Histopathologic type    
  Well 56     20     36 
0.396* 
Moderately + poorly 44     12     32 
__________________________________________________________________________________________________________ 
*Fisher’s exact test. 
†p < 0.05. 
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